LINC00628: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC00628

NCBI ID: G127841

LINC00628

Other Name(s): long intergenic non-protein coding RNA 628 | Long intergenic non-protein coding RNA 628

LINC00628: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Introduction

LINC00628 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various organisms, including humans. It has a unique feature, which is the presence of a highly conserved open reading frame (ORF) that is annotated with gene regulation-related domains. This unique property makes LINC00628 an attractive candidate for drug targeting and as a biomarker. In this article, we will explore the properties and potential applications of LINC00628 as a drug target and biomarker.

Structure and Expression

LINC00628 is a 22.9 kilobase (kb) RNA molecule with a single exon. It has a unique 5'-end that is specific to the human body, which is a feature that is common in some plant and fungal genomes. The 3'-end of the RNA contains a unique 7-base insertion that is specific to LINC00628.

Expression of LINC00628

LINC00628 is expressed in various tissues and cells of the human body, including the brain, heart, and liver. It is expressed at different levels, and its expression level is highly dependent on the cell type and the experimental conditions. LINC00628 has been shown to be involved in various cellular processes, including cell growth, apoptosis, and inflammation.

Drug Targeting

LINC00628 is a good candidate for drug targeting due to its unique property, which is the presence of a highly conserved open reading frame (ORF) that is annotated with gene regulation-related domains. These domains are known to be involved in the regulation of gene expression, and they can be potential drug targets.

One of the potential drug targets for LINC00628 is the protein p16INK4a. p16INK4a is a transcription factor that is involved in the regulation of cell growth, apoptosis, and cancer progression. LINC00628 has been shown to interact with p16INK4a, and this interaction may be a potential drug target for LINC00628.

Biomarker

LINC00628 can also be used as a biomarker for various diseases, including cancer. It has been shown to be involved in the regulation of cell apoptosis, which is a common occurrence in cancer cells. LINC00628 has been shown to be expressed in various types of cancer. , including brain, breast, and colorectal cancer.

Conclusion

LINC00628 is a long intergenic non-protein-coding RNA that has unique properties, including the presence of a highly conserved open reading frame (ORF) that is annotated with gene regulation-related domains. These properties make LINC00628 an attractive candidate for drug targeting and as a biomarker. The interaction between LINC00628 and the protein p16INK4a suggests that LINC00628 may be a potential drug target for cancer. Additionally, the expression of LINC00628 in various tissues and cells of the human body makes it a potential biomarker for cancer. Further research is needed to confirm these findings and to explore the potential applications of LINC00628 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 628

The "LINC00628 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00628 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets